Nevada 2019 Regular Session Status: Enacted

SB 276 — Directs the Legislative Commission to appoint a committee to conduct an interim study concerning the costs of prescription drugs. (BDR 57-599)

Last action — Chapter 324.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed Assembly
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced March 14, 2019. Enacted.

Prognosis

Advancing 50% · moderate confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

AN ACT relating to prescription drugs; directing the Legislative Commission to appoint a committee to conduct an interim study concerning the costs of prescription drugs in this State; and providing other matters properly relating thereto.

Bill Text

What changed in the latest version

50 added · 86 removed

50 line(s) added, 86 removed.

→
Previous
Latest
(Reprinted with amendments adopted on April 19, 2019) FIRST REPRINT S.B.
Senate Bill No.
276 SENATE B ILLN O.
276–Senator Cancela CHAPTER..........
276–SENATOR C ANCELA M ARCH 14, 2019 ____________ Referred to Committee on Commerce and Labor SUMMARY—Directs the Legislative Commission to appoint a committee to conduct an interim study concerning the costs of prescription drugs.
(BDR 57-599) FISCAL NOTE:
Effect on Local Government:
May have Fiscal Impact.
Effect on the State:
Yes.
~ EXPLANATION – Matter in bolded italics is new;
matter between brackets [omitted material] is material to be omitted.
Legislative Counsel’s Digest:
LegThis bill directs the Legislative Commission to appoint a committee to conduct an interim study concerning the issue of the costs of prescription drugs in this State and the impact of rebates, reductions in price and other remuneration from drug manufacturers on prescription drug prices.
an interim study concerning the issue of the costs of prescription drugs in this State and the impact of rebates, reductions in price and other remuneration from drug manufacturers on prescription drug prices.
EXPLANATION – Matter in bolded italics is new;
matter between brackets [omitted material] is material to be omitted.
Section 1.
Sections 1-24.
2.
(Deleted by amendment.) Sec.
3.
(Deleted by amendment.) Sec.
4.
(Deleted by amendment.) Sec.
5.
(Deleted by amendment.) Sec.
6.
(Deleted by amendment.) Sec.
7.
(Deleted by amendment.) Sec.
8.
(Deleted by amendment.) Sec.
9.
(Deleted by amendment.) Sec.
10.
(Deleted by amendment.) Sec.
11.
(Deleted by amendment.) - *SB276_R1* – 2 – Sec.
12.
(Deleted by amendment.) Sec.
13.
(Deleted by amendment.) Sec.
14.
(Deleted by amendment.) Sec.
Show all 68 changed rows (28 more)
Previous
Latest
15.
(Deleted by amendment.) Sec.
16.
(Deleted by amendment.) Sec.
17.
(Deleted by amendment.) Sec.
18.
(Deleted by amendment.) Sec.
19.
(Deleted by amendment.) Sec.
20.
(Deleted by amendment.) Sec.
21.
(Deleted by amendment.) Sec.
22.
(Deleted by amendment.) Sec.
23.
(Deleted by amendment.) Sec.
24.
(Deleted by amendment.) Sec.
Senate;
(c) One member appointed by the Minority Leader of the Senate;
andmember appointed by the Minority Leader of the (d) One member appointed by the Minority Leader of the Ass3.
and (d) One member appointed by the Minority Leader of the Assembly.
3.
In conducting the study, the interim committee shall consult with and solicit input from persons and organizations with expertise in matters relevant to the costs of prescription drugs and the impact of rebates, reductions in price and other remuneration from manufacturers on prescription drug prices.
In conducting the study, the interim committee shall consult in matters relevant to the costs of prescription drugs and the impact of rebates, reductions in price and other remuneration from manufacturers on prescription drug prices.
(b) The impact of rebates, reductions in price and other remuneration from manufacturers on the overall costs of prescription drugs in this State;
- 80th Session (2019) – 2 – (b) The impact of rebates, reductions in price and other remuneration from manufacturers on the overall costs of prescription drugs in this State;
and (c) Opportunities and options for lowering the costs of prescription drugs to make those drugs more affordable for the residents of this State.
and (c) Opportunities and options for lowering the costs of residents of this State.ke those drugs more affordable for the 6.
- *SB276_R1* – 3 – 6.
H - *SB276_R1*
~~~~~ 19 - 80th Session (2019)
⬇ Download PDF
View plain text versions (3)

Amendments

1 amendment

Click Show changes on an amendment above to see how it modifies the bill.

Action History

  1. Chapter 324.

  2. Approved by the Governor.

  3. Enrolled and delivered to Governor.

  4. From committee: Do pass. Declared an emergency measure under the Constitution. Read third time. Passed. Title approved. (Yeas: 40, Nays: None, Excused: 1, Vacant: 1.) To Senate. In Senate. To enrollment.

  5. In Assembly. Read first time. Referred to Committee on Legislative Operations and Elections. To committee.

  6. From printer. To engrossment. Engrossed. First reprint. Notice of exemption. Read third time. Passed, as amended. Title approved, as amended. (Yeas: 21, Nays: None.) To Assembly.

  7. From committee: Amend, and do pass as amended. Placed on Second Reading File. Read second time. Amended. (Amend. No. 404.) To printer.

  8. Notice of eligibility for exemption.

  9. From printer. To committee.

  10. Read first time. Referred to Committee on Commerce and Labor. To printer.

Sponsors

  • Senator Yvanna Cancela · Primary

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 66 not signed on

Sponsors (1)

  • Senator Yvanna Cancela

Co-sponsors (0)

None.

Not signed on (66)

66 members have not signed on to this bill.

Show all 66 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 276 do?
AN ACT relating to prescription drugs; directing the Legislative Commission to appoint a committee to conduct an interim study concerning the costs of prescription drugs in this State; and providing other matters properly relating thereto.
Who sponsors SB 276?
SB 276 is sponsored by Senator Yvanna Cancela.
What is the current status of SB 276?
This bill has been enacted into law. Introduced March 14, 2019. Enacted.
Where can I track SB 276?
Track SB 276 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 276

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 276

Last checked for changes 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →